BATF3 (Basic Leucine Zipper ATF-Like Transcription Factor 3)

Its capability to overcome tumor resistance and the underlying mechanism were further investigated in a well-established tumor model. Our findings highlight the cooperative role of STING activation and IDO1 blockade within cDC1s and introduce an integrated drug delivery system to combat immune tolerance in cancer therapy.

Our results demonstrated that each Batf family member has distinct functions in CD8+ T cells. These findings help us understand the roles of the Batf family members in CD8+ T cells and contribute to the development of optimized adoptive T cell therapies against cancer.

BAIT further synergizes with treatments that increase local tumor antigen load, such as chemotherapy and radiotherapy, to eradicate cold tumors and prevent recurrence. Its feasibility is validated in human patient samples.

In line with our preclinical findings, our phase 1 trial of anti-CD40 shows that circulating IL-12, IFNγ, and IL-10 increase in response to anti-CD40, while our phase 1b/2 PRINCE study shows that lower circulating IL-10 is associated with favorable overall survival specifically among anti-CD40-treated patients. Finally, we found that neutrophil expansion with granulocyte colony stimulating factor (G-CSF) is associated with improved overall survival, specifically in patients treated with anti-CD40, suggesting that this pathway may be amenable to therapeutic intervention in patients with advanced cancer.

IFNα2b enchances dendritic cell maturation and promotes TH1-skewed anti-tumor immune responses, supporting its potential as an adjuvant to enhance DC-based immunotherapy in NSCLC patients.

This study demonstrates that adjuvants can facilitate recruitment of cDC1s to the peritoneal cavity, a feature that may contribute to the effectiveness of i.p. administration on elicitation of CD8 T cell responses. Furthermore, we demonstrate that CAF09b-induced CD8 T cell responses require BATF3-dependent cDC1 cells. Understanding cDC1 and CD8 T cell dynamics via different immunization routes may aid in the design of more effective vaccine strategies.

This sequential, cis-regulated activation appears to be the core mechanism for progressively tuning chromatin accessibility, ensuring robust lineage commitment. While its molecular basis is obscure, this dependency offers a new model for understanding genomic regulation in development.

This review explored how the BATF family regulates various signaling pathways and cytokines in the tumor microenvironment, thereby participating in tumor occurrence, proliferation, invasion, and metastasis, and discussed the potential of targeting the BATF family for tumor treatment. Taken together, the BATF family emerges as an important regulator of tumor immunity with potential relevance as biomarkers or therapeutic targets.

Given the immune-enhancing effects and excellent safety profile, pomalidomide should be further investigated as an immune-enhancing strategy for an HIV cure.

Overall, LSD1 inhibition in tumor cells upregulates MHC-I expression and stimulates CXCL9 secretion by DCs to enhance antigen presentation and promote CD8+ T cell activation via the CXCL9-CXCR3 signaling axis, resulting in increased IFNγ production. This may have implications for treating poorly immunogenic and immunotherapy-resistant cancers.

Mechanistically, Il27 and Cxcl10 transcription was induced by synergizing Toll-like receptor (TLR) and CD40 signals and driven by coinduced transcription factor BATF3, which directly targeted these genes. By applying a discovery framework focusing on regulatory cells, our findings expand the recognized scope of B cell regulatory functions.

This study reveals immune-molecular interactions in GBM, identifies AEBP1/EFEMP2 as prognostic markers, and proposes targeted therapies for personalized treatment.